Please provide your email address to receive an email when new articles are posted on . Hepatocellular carcinoma accounts for approximately 90% of all primary liver cancer cases, according to Zhen-Wei ...
Clascoterone cream 1% plus adapalene gel 0.3% offers an effective, well-tolerated topical option for moderate to severe acne, ...
Early ASH 2025 data suggest sonrotoclax is a promising therapy in MCL, supporting a broader shift toward chemo-free, ...
A study was conducted to compare cardiovascular outcomes for single-pill antihypertensive combination therapy and identical multiple pill therapy. Risk for CV events and all-cause mortality is ...
49% of patients treated with Opdivo plus Yervoy were alive at 6.5 years and 77% of these patients remained treatment-free Data to be featured in an oral presentation during the 2021 American Society ...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, ...
Combination treatment with two PD-1 inhibitors — Yervoy and Opdivo — did not improve survival without cancer recurrence compared with Opdivo alone in patients with high-risk melanoma, a type of skin ...
Nomogram to predict risk of 30-day mortality for patients with disseminated malignancy undergoing surgical intervention. Background: There is wide variability in the treatment of metastatic breast ...
ORLANDO, Fla.--The combination of chemotherapies 5FU and oxaliplatin compared to 5FU alone after surgery for colon cancer decreases colon cancer recurrence and promotes longer survival for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback